NK Cell Therapy Pipeline, Clinical Trials Studies, Emerging Drugs, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "NK Cell Therapy Pipeline Insight, 2023," report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the NK Cell Therapy Pipeline Report
• DelveInsight's NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
• The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
• Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, FT500, Pembrolizumab, NKX019, Ipilimumab, and others.
• October 2023: Dana-Farber Cancer Institute announced a study of phase 1 clinical trials for Interleukin-15 Superagonist (N-803, Ipilimumab and Cetuximab. This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This is a three-part, non-randomized, open label, single site Phase 1 study. The purpose of this research study is to obtain information on the safety and effectiveness of this combination of study drugs to treat advanced head and neck. The experimental combination therapy in this study involves CIML NK cells from a haploidentical donor (meaning cells from another person with similar immune proteins), IL-15, participants in cohort 2 will also receive ipilimumab, and participants in cohort 3 will receive cetuximab.
• October 2023: Karolinska Institutet announced a study of Phase 2 clinical trials for CellProtect and Isatuximab. Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT. Isatuximab in combination with CellProtect (ISA/CellProtect experimental arm), or Isatuximab (ISA, control arm). Randomization will be at diagnosis and before the start of the treatment for patients eligible for SCT. Treatment administration will start within 100 days from AST date. Patients will be treated until disease progression (max 3 years), unacceptable adverse event (AE), and patient's decision to stop the study treatment, death or any other reasons, whichever occurs first.
• September 2023: NKGen Biotech Inc. announced a study of Phase 1 clinical trials for SNK02. The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are:- Is SNK02 safety and tolerable when administered weekly as an intravenous infusion and What is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy treatment.
• August 2023: Bio haven Pharmaceutical Inc. announced a study of Phase 1 clinical trials for CIML NK Cells plus KP1237 and low dose IL-2. This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT). A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission.

Request a sample and discover the recent advances in NK Cell Therapy Treatment Drugs @ NK Cell Therapy Pipeline Report- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the NK Cell Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NK Cell Therapy NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

NK Cell Therapy Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm.

Find out more about NK Cell Therapy Therapeutics Assessment @ NK Cell Therapy Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapy Emerging Drugs Profile
• NKTR-214: Nektar therapeutics
• Monalizumab: Innate Pharma
• Bemarituzumab: Five Prime Therapeutics
• ALT 803: ImmunityBio
• CellProtect: XNK Therapeutics
• K-NK002: Kiadis Pharma
• NK-92: ImmunityBio
• WU-NK-101: Wugen
• Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
• ALECSAT: CytoVac

NK Cell Therapy Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the NK Cell Therapy therapies. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

DelveInsight's NK Cell Therapy Pipeline Report covers around 185+ products under different phases of clinical development like-
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

NK Cell Therapy Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as-

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Learn more about the emerging NK Cell Therapy Pipeline Therapies @ NK Cell Therapy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the NK Cell Therapy Pipeline Report
• Coverage- Global
• NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
• NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, FT500, Pembrolizumab, NKX019, Ipilimumab, and others.

Dive deep into rich insights for new drugs for NK Cell Therapy Treatment, Visit @ NK Cell Therapy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. NK Cell Therapy Executive Summary
3. Natural Killer (NK) cell therapy: Overview
4. NK Cell Therapy Pipeline Therapeutics
5. NK Cell Therapy Therapeutic Assessment
6. Late Stage Products (Phase III)
7. NKTR-214: Nektar therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. CellProtect: XNK Therapeutics
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Natural Killer (NK) cell therapy Key Companies
17. Natural Killer (NK) cell therapy Key Products
18. Natural Killer (NK) cell therapy- Unmet Needs
19. Natural Killer (NK) cell therapy- Market Drivers and Barriers
20. Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
21. Natural Killer (NK) cell therapy Analyst Views
22. Natural Killer (NK) cell therapy Key Companies
23. Appendix

For further information on the NK Cell Therapy Pipeline therapeutics, reach out to NK Cell Therapy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recently Published Most Important Links-
https://jobs.recruitingblogs.com/employers/2384764-delveinsight
http://samus.vforums.co.uk/profile/dennydonesdi
http://supportskin.vforums.co.uk/profile/dennydonesdi
http://wwa.vforums.co.uk/profile/dennydonesdi
http://music.vforums.co.uk/general/2838/delveinsight
http://nuchinuxri.vforums.co.uk/profile/dennydones91021
http://raf.vforums.co.uk/profile/dennydonesdi
http://france.vforums.co.uk/Suggestions/1797/market-research-reports
http://thecir.vforums.co.uk/profile/dennydonesdi
http://lol.vforums.co.uk/profile/dennydonesdi
https://www.openlearning.com/u/havensmith-s2ry19/
https://dennydones9.cgsociety.org/profile
https://www.f6s.com/member/denny-dones
https://www.minecraftforum.net/members/dennydones9?__cf_chl_tk=ljVLvJPBSq9.mVHsoWgwPjJb0A23nSrkftR8IxJ5Wec-1697717482-0-gaNycGzNDTs
https://coderwall.com/p/4tufta/herpes-zoster-market-trends-and-developments-in-2023
https://midi.org/forum/20192-herpes-zoster-market-future-prospects-in-2023
https://tapas.io/ybhardwaj
https://photozou.jp/user/top/3328982
https://b.hatena.ne.jp/entry?url=https%3A%2F%2Fwww.delveinsight.com%2Freport-store%2Fherpes-zoster-market
https://www.thingiverse.com/dennydones9/designs
https://soundcloud.com/dennydones
https://experiment.com/users/dennydones9
https://lichess.org/@/dennydones9
https://www.nicovideo.jp/user/130955053
https://menwiki.men/wiki/Main_Page
https://historydb.date/wiki/2_Bonus_Paling_Penting_di_Agen_Sbobet88_Terpercaya
https://mozillabd.science/wiki/Main_Page
https://championsleage.review/wiki/Main_Page
https://timeoftheworld.date/wiki/Main_Page
https://funsilo.date/wiki/Main_Page
https://opensourcebridge.science/wiki/Main_Page
https://scientific-programs.science/wiki/Main_Page
https://lovewiki.faith/wiki/Main_Page
https://influence.co/dennydones9999
https://www.awwwards.com/dennydones9999/
https://www.producthunt.com/discussions/pharma-competitive-intelligence-tracking-services-navigating-the-pharmaceutical-landscape
https://forum.ngs.ru/profile/3132957/
https://zrzutka.pl/profile/delveinsight-295941
https://sound-social.com/story5059347/healthcare-competitive-intelligence-tracking-services
https://socialmarkz.com/story5419072/healthcare-competitive-intelligence-tracking-services
https://network-373.mn.co/posts/41603294
https://www.hogwartsishere.com/1562170/
https://www.renderosity.com/users/id:1400373
https://hitrecord.org/users/dennydones9999/records
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.atlasobscura.com/users/dennydones1
https://freedomlifestyle.mn.co/posts/41604435
https://socialmediainuk.com/story15310402/healthcare-competitive-intelligence-tracking-services
https://onlinedhan.mn.co/posts/41604571
https://skeleton-girls.mn.co/posts/41716585
https://network-89593.mn.co/posts/41716670
https://shaman-leaders.mn.co/posts/41716806
https://walkinvirtualclinics.mn.co/posts/41716883
https://machineintelligence.mn.co/posts/the-role-of-healthcare-partner-identification-services
https://vjudge.net/user/dennydones9999
https://yizhanverse.mn.co/posts/41717293
https://demo.plushforums.com/profile/18/denny-dones
https://www.sideprojectors.com/user/profile/69119
https://bookmarkstumble.com/story16655285/healthcare-partner-identification-services
https://bookmarkstime.com/story15535182/healthcare-partner-identification-services
http://baigasciedil.vforums.co.uk/profile/dennydones9999
http://weareone.vforums.co.uk/profile/dennydones9999
http://astarsuzuki.vforums.co.uk/profile/dennydones9999
http://proweb.vforums.co.uk/action/view_profile/user/dennydones9999
http://taresources.vforums.co.uk/action/view_profile/user/dennydones9999
http://gothicskin.vforums.co.uk/profile/dennydones9999
http://graphics.vforums.co.uk/profile/dennydones9999
http://clapecasna.vforums.co.uk/profile/dennydones9999
http://freuniontest.vforums.co.uk/profile/dennydones9999
http://whatwentwrong.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://system.vforums.co.uk/profile/dennydones9999
http://upsclan.vforums.co.uk/profile/dennydones999911
http://hairetevi.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://vfscomp2.vforums.co.uk/profile/dennydones9999
http://gamersgetaway.vforums.co.uk/profile/dennydones9999
http://surreyjobs.vforums.co.uk/profile/dennydones9999
http://support2.vforums.co.uk/profile/dennydones9999
http://swlsupport.vforums.co.uk/profile/dennydones9999
http://slipalimer.vforums.co.uk/profile/dennydones990099
http://art.vforums.co.uk/profile/dennydones990099
http://styles.vforums.co.uk/profile/dennydones990099
http://ghofertech.vforums.co.uk/profile/dennydones990099
http://dcdesign.vforums.co.uk/profile/dennydones990099
http://musicspot.vforums.co.uk/profile/dennydones990099
http://prov.vforums.co.uk/profile/dennydones990099
http://russell.vforums.co.uk/profile/dennydones990099
http://makethemes.vforums.co.uk/profile/dennydones990099
http://famousads.vforums.co.uk/profile/dennydones990099
http://pinkness.vforums.co.uk/profile/dennydones990011
http://elseandrew.vforums.co.uk/profile/dennydones99
http://suigacartsing.vforums.co.uk/profile/dennydones99
http://calanaera.vforums.co.uk/profile/dennydones99
http://legstudios.vforums.co.uk/action/view_profile/user/dennydones99
http://idirectory-old.vforums.co.uk/profile/dennydones99
http://skegness.vforums.co.uk/profile/dennydones99
http://futurexistence.vforums.co.uk/action/view_profile/user/dennydones99
http://codes.vforums.co.uk/profile/dennydones99
http://isgicaflo.vforums.co.uk/profile/dennydones99
http://profewovxi.vforums.co.uk/profile/dennydones99
http://zacsplace.vforums.co.uk/profile/dennydones99
http://sneeznavilas.vforums.co.uk/profile/dennydones99
http://coderspalace.vforums.co.uk/profile/dennydones991199
http://guide.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://rs2devolution.vforums.co.uk/action/view_profile/user/dennydones99
http://englishporcelain.vforums.co.uk/profile/dennydones99
https://scratchgram-2nd-instagram2.mn.co/posts/navigating-the-healthcare-landscape-with-competitive-intelligence-tracking-services
https://network-84066.mn.co/posts/42686849
https://www.canadavideocompanies.ca/author/dennydones1/
https://monvelli.mn.co/posts/42687788
https://fishjines.mn.co/posts/42688039
https://diecast64.mn.co/posts/42688112
https://mighty-men.mn.co/posts/42688183
https://team-clo.mn.co/posts/unveiling-the-power-of-healthcare-competitive-intelligence-tracking-services
https://stackoverflow.com/users/22614429/denny-dones?tab=profile
https://waarnemingen.be/users/791405/
https://keywebco.mn.co/posts/healthcare-competitive-intelligence-tracking-services-unveiling-the-future-of-healthcare-strategy

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.